BIIB - Biogen Inc. Stock Price and Quote

BIIB [NASD]

Healthcare | Drug Manufacturers - General | USA

Index	NDX, S&P 500	P/E	12.91	EPS (ttm)	20.92	Insider Own	0.10%	Shs Outstand	143.80M	Perf Week	1.27%
Market Cap	38.31B	Forward P/E	16.36	EPS next Y	16.51	Insider Trans	-7.28%	Shs Float	143.01M	Perf Month	0.12%
Income	3.05B	PEG	8.80	EPS next Q	3.38	Inst Own	88.60%	Short Float / Ratio	1.38% / 2.01	Perf Quarter	-3.45%
Sales	10.17B	P/S	3.77	EPS this Y	100.60%	Inst Trans	0.85%	Short Interest	1.98M	Perf Half Y	37.69%
Book/sh	93.17	P/B	2.90	EPS next Y	6.29%	ROA	12.40%	Target Price	321.07	Perf Year	27.75%
Cash/sh	34.48	P/C	7.83	EPS next 5Y	1.47%	ROE	24.70%	52W Range	187.16 - 311.88	Perf YTD	-2.67%
Dividend	-	P/FCF	33.49	EPS past 5Y	3.70%	ROI	9.80%	52W High	-13.58%	Beta	0.18
Dividend %	-	Quick Ratio	2.60	Sales past 5Y	-3.70%	Gross Margin	77.60%	52W Low	44.01%	ATR	5.82
Employees	8725	Current Ratio	3.00	Sales Q/Q	-6.90%	Oper. Margin	25.20%	RSI (14)	50.96	Volatility	2.07% 2.13%
Optionable	Yes	Debt/Eq	0.47	EPS Q/Q	51.60%	Profit Margin	29.90%	Rel Volume	0.26	Prev Close	269.98
Shortable	Yes	LT Debt/Eq	0.47	Earnings	Feb 15 BMO	Payout	0.00%	Avg Volume	985.56K	Price	269.52
Recom	2.20	SMA20	1.57%	SMA50	-2.59%	SMA200	6.78%	Volume	221,419	Change	-0.17%

Oct-26-22

Upgrade

Goldman

Neutral → Buy

$220 → $370

Oct-13-22

Upgrade

Stifel

Hold → Buy

$223 → $299

Oct-07-22

Upgrade

Argus

Hold → Buy

$300

Sep-28-22

Upgrade

Robert W. Baird

Neutral → Outperform

$224 → $340

Sep-28-22

Upgrade

Mizuho

Neutral → Buy

$207 → $270

Sep-28-22

Upgrade

BMO Capital Markets

Market Perform → Outperform

$217 → $360

Apr-18-22

Upgrade

Wells Fargo

Equal Weight → Overweight

$235 → $265

Mar-08-22

Downgrade

Stifel

Buy → Hold

$304 → $223

Mar-03-22

Upgrade

RBC Capital Mkts

Sector Perform → Outperform

$227 → $248

Feb-04-22

Reiterated

Wolfe Research

Peer Perform

$244 → $217

Show Previous Ratings

Mar-27-23 06:15PM	Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know Zacks
11:42AM	Ionis (IONS) Posts New Upbeat Data From Amyloidosis Drug Study Zacks
11:15AM	Morningstar \| A Weekly Summary of Stock Ideas and Developments in the Companies We Cover Morningstar Research
Mar-26-23 09:00AM	Biogen Inc. (NASDAQ:BIIB) is a favorite amongst institutional investors who own 88% Simply Wall St.
08:45AM	Morningstar \| A Weekly Summary of Stock Ideas and Developments in the Companies We Cover Morningstar Research
04:03PM	Loading…
Mar-23-23 04:03PM	Biogen Pops But Ionis Hands Back Gains After ALS Drug Wins A Key Endorsement Investor's Business Daily
01:56PM	7 Blue-Chip Stocks Sitting in the Sweet Spot InvestorPlace
01:51PM	Biotech Stock Roundup: ALT Obesity Data, GILD Exercises Option, INCY Drug Approval Zacks
10:53AM	Biogen (BIIB) Gets Positive FDA Panel Vote for Tofersen NDA Zacks
09:25AM	Ionis Rockets As Biogen-Partnered ALS Drug Wins Key Endorsement Investor's Business Daily
09:12AM	FDA Adcomm Says Benefit-Risk Profile Favor Biogen's Tofersen For Inherited Neuro Disorder Benzinga
06:09AM	The Petri Dish: Takeda scores win from Nimbus licensing deal; Biogen exits partnership American City Business Journals
Mar-22-23 08:31PM	Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS GlobeNewswire
05:29PM	UPDATE 3-US FDA panel backs accelerated approval for Biogen's ALS drug Reuters
Mar-21-23 06:00PM	Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know Zacks
08:59AM	Loading…
08:59AM	Despite Failed Phase 3 Study, FDA Staff Says Biogen's ALS Drug May Have Clinical Benefit Benzinga
Mar-20-23 12:25PM	Two Big Pharma Companies Bow Out Of Neurology Drug Partnerships With Sangamo Benzinga
09:51AM	UPDATE 2-FDA staff says safety issues with Biogen's ALS drug to not prevent approval Reuters
Mar-19-23 05:30AM	Should You Buy Biogen Before a Big July Decision? Motley Fool
Mar-17-23 11:30AM	Biogen Inc. (BIIB) Down 2.3% Since Last Earnings Report: Can It Rebound? Zacks
08:00AM	Is There An Opportunity With Biogen Inc.'s (NASDAQ:BIIB) 27% Undervaluation? Simply Wall St.
Mar-16-23 02:00PM	Alzheimer's Association Launches Grassroots Level Lobbying For Medicare Coverage Of Alzheimer's Treatments Benzinga
08:43AM	Biogen (BIIB) Up 29% in a Year Despite Multiple Challenges Zacks
06:30AM	Biogen Receives Favorable Decision from Court of Justice of the European Union Relating to TECFIDERA® (dimethyl fumarate) Regulatory Data and Marketing Protection GlobeNewswire
Mar-15-23 06:00PM	Biogen Inc. (BIIB) Gains As Market Dips: What You Should Know Zacks
Mar-14-23 06:15PM	Biogen Inc. (BIIB) Gains But Lags Market: What You Should Know Zacks
10:52AM	The VA Will Pay for Leqembi. Its a Step in Right Direction for Biogen. Barrons.com
10:23AM	1 Reason to Buy Biogen Stock, and 1 Reason to Sell Motley Fool
08:57AM	Veterans Health to cover Eisai, Biogens new Alzheimers drug MarketWatch
07:30AM	Biogen Appoints Chuck Triano as Head of Investor Relations GlobeNewswire
05:05PM	Loading…
Mar-13-23 05:05PM	Veterans Affairs to Be First Major Insurer to Cover Alzheimers Drug Leqembi The Wall Street Journal
05:01PM	UPDATE 1-US VA to cover Eisai, Biogen Alzheimer's treatment Leqembi Reuters
Mar-09-23 04:05PM	Eli Lilly's Decade-Long Effort In Alzheimer's Disease Just Failed Investor's Business Daily
09:33AM	Lilly's (LLY) Alzheimer Drug Fails Late-Stage Prevention Study Zacks
Mar-08-23 06:00PM	Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know Zacks
07:30AM	Caroline Dorsa to Succeed Stelios Papadopoulos as Chair of Biogen Board of Directors GlobeNewswire
Mar-07-23 06:50AM	The Data Will Speak Louder Than Powell. Fed Rate Is Veering Toward 6%. Barrons.com
Mar-06-23 04:38PM	FDA to decide on full approval of Alzheimer's treatment Leqembi in early July Fox Business
12:46PM	Eisai-Biogen Seek Complete FDA Approval For Its Second Alzheimer's Treatment Benzinga
11:38AM	FDA Will Weigh Full Approval for Alzheimers Drug. Why It Matters for Biogen Stock. Barrons.com
08:16AM	Biogen (BIIB), Eisai Seek Full Nod for Alzheimer Drug Leqembi Zacks
Mar-05-23 06:30PM	FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease PR Newswire
Mar-01-23 02:43PM	UPDATE 1-Genentech sues Biogen for royalties on blockbuster MS drug Reuters
12:04PM	Genentech sues Biogen for royalties on blockbuster MS drug Reuters
Feb-28-23 08:14PM	Reatas stock soars 150% after FDA approves rare-disease drug amid uncertainty about approach to neuroscience treatments MarketWatch
06:31PM	Reatas stock nearly triples after FDA approves rare-disease drug amid uncertainty about approach to neuroscience treatments MarketWatch
05:39PM	FDA approves Reatas rare disease drug amid questions about changes to the regulatory environment for neuroscience treatments MarketWatch
01:41PM	FDA neurosciences chief Billy Dunn to leave immediately, analysts raise concern Reuters
Feb-27-23 06:30PM	BIOLOGICS LICENSE APPLICATION FOR LECANEMAB DESIGNATED FOR PRIORITY REVIEW BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION PR Newswire
06:30PM	Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration GlobeNewswire
02:30PM	Amyloid Gains Converts in Debate Over Alzheimers Treatments The Wall Street Journal
Feb-23-23 06:00AM	We Think Biogen (NASDAQ:BIIB) Can Stay On Top Of Its Debt Simply Wall St.
Feb-22-23 09:07PM	UPDATE 1-U.S. Medicare says no change to Alzheimer's drug restrictions Reuters
Feb-19-23 06:00AM	Biogen Inc.'s (NASDAQ:BIIB) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong? Simply Wall St.
Feb-16-23 06:49PM	Biogen Inc. (NASDAQ:BIIB) Q4 2022 Earnings Call Transcript Insider Monkey
01:41PM	Biogen has nearly made good on reported plan to cut 1,000 jobs in 2022 American City Business Journals
11:48AM	Biotech Stock Roundup: BIIB's Q4 Results, EBS and BPMC Offer Updates Zacks
Feb-15-23 04:03PM	Biogen Slumps On Limited Alzheimer's Sales Expectations As Pressure Points Mount Investor's Business Daily
02:30PM	Biogen (BIIB) Q4 2022 Earnings Call Transcript Motley Fool
01:58PM	Analyst Report: Biogen Inc. Morningstar Research
01:16PM	Biogen Boss Turns Corner on Alzheimers Miscues The Wall Street Journal
12:26PM	Compared to Estimates, Biogen Inc. (BIIB) Q4 Earnings: A Look at Key Metrics Zacks
11:43AM	Leqembi: Medicare coverage needs a convincing set of evidence for FDA approval, analyst says Yahoo Finance Video
10:57AM	Biogen (BIIB) Beats Q4 Earnings & Sales Estimates, Stock Up Zacks
10:53AM	Biogen hints at more cost-cutting under new CEO as revenue falls American City Business Journals
09:47AM	Why Biogen Stock Is Falling Today Benzinga
09:13AM	Drugmaker Biogen tops 4Q forecasts despite sales slip AP Finance
08:54AM	Biogen Inches Higher On Quarterly Beat, Guides To 'Modest' Alzheimer's Drug Sales Investor's Business Daily
08:25AM	Biogen Inc. (BIIB) Q4 Earnings and Revenues Beat Estimates Zacks
07:53AM	UPDATE 2-Biogen CEO bets on Alzheimer's drug, pipeline to return to growth Reuters
07:24AM	Biogens stock gains after company beats Q4 revenue and earnings expectations MarketWatch
07:24AM	Biogen Tops Profit Expectations as Alzheimers and Depression Drugs Remain in Focus Barrons.com
07:04AM	Biogen CEO bets on Alzheimer's drug, pipeline to return to growth Reuters
07:01AM	Investors in Biogen (NASDAQ:BIIB) have made a respectable return of 35% over the past year Simply Wall St.
03:00AM	Airbnb, TripAdvisor, Tesla rise premarket; Barclays, Devon Energy fall Investing.com
Feb-14-23 05:23PM	Drugs for Alzheimers, Depression, Are in Focus as Biogen Reports Earnings Barrons.com
Feb-13-23 07:56AM	Weekly Stock List Argus Research
Feb-11-23 07:00AM	With 88% institutional ownership, Biogen Inc. (NASDAQ:BIIB) is a favorite amongst the big guns Simply Wall St.
Feb-10-23 01:40PM	25 Biggest Massachusetts Companies and Stocks Insider Monkey
Feb-08-23 02:00PM	2 Top Biotech Stocks Defying the Bear Market Motley Fool
10:00AM	Biogen Inc. (BIIB) Reports Next Week: Wall Street Expects Earnings Growth Zacks
09:47AM	Will Biogen (BIIB) Beat Estimates This Earnings Season? Zacks
Feb-07-23 10:17AM	Sage and Biogen's NDA for Depression Drug Gets Priority Review Zacks
10:16AM	Strong Start, but Challenges Persist Argus Research
09:00AM	Is Biogen Inc. (NASDAQ:BIIB) Trading At A 24% Discount? Simply Wall St.
Feb-06-23 06:00PM	Biogen Inc. (BIIB) Gains As Market Dips: What You Should Know Zacks
12:14PM	Sage Therapeutics-Biogen Partnered Depression Candidate Under Priority FDA Review, Analyst Says Its 'Incrementally Positive' Benzinga
06:30AM	Sage Therapeutics and Biogen Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression Business Wire
06:30AM	Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression GlobeNewswire
Feb-01-23 04:10PM	The 7 Most Undervalued Nasdaq Stocks to Buy in February 2023 InvestorPlace
09:53AM	Why the FDA's Rejection of Eli Lilly's Alzheimer's Drug Is Actually Great News for the Stock Motley Fool
Jan-30-23 06:00PM	Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know Zacks
09:38AM	15 Biggest Neuroscience Companies in the World Insider Monkey
Jan-29-23 07:44PM	UPDATE 1-Japan gives priority review status to Alzheimer's drug developed by Eisai, Biogen Reuters
06:30PM	Lecanemab Receives Priority Review Status in Japan GlobeNewswire
02:35PM	15 Most Famous Hedge Fund Managers and Their Top Stock Picks Insider Monkey
Jan-27-23 09:57AM	Biogen (BIIB) & Eisai's Lecanemab Secures EMA's MAA Acceptance Zacks
Jan-26-23 07:22PM	UPDATE 1-EU regulator accepts for review Alzheimer's treatment from Eisai-Biogen Reuters
06:30PM	Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimers Disease Accepted by European Medicines Agency GlobeNewswire
07:30AM	Is Biogen Stock a Buy Now? Motley Fool

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It also provides RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, immunology related diseases, neurovascular disorders, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. Biogen Inc. has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Singhal Priya	Head of Development	Mar 02	Option Exercise	0.00	297	0	3,554	Mar 06 06:13 PM
Singhal Priya	Head of Development	Feb 17	Option Exercise	0.00	460	0	3,951	Feb 22 05:07 PM
Kramer Robin	Chief Accounting Officer	Feb 17	Option Exercise	0.00	512	0	3,844	Feb 22 05:01 PM
MCDONNELL MICHAEL R	EVP, Chief Financial Officer	Feb 17	Option Exercise	0.00	2,561	0	10,147	Feb 22 05:03 PM
Izzar Rachid	Head of Global Product Strat.	Feb 17	Option Exercise	0.00	767	0	5,884	Feb 22 04:57 PM
Gregory Ginger	EVP, Human Resources	Feb 17	Option Exercise	0.00	1,792	0	11,072	Feb 22 04:54 PM
ALEXANDER SUSAN H	EVP Chief Legal Off & Corp Sec	Feb 17	Option Exercise	0.00	1,920	0	46,840	Feb 22 04:49 PM
ALEXANDER SUSAN H	EVP Chief Legal Off & Corp Sec	Feb 10	Option Exercise	0.00	4,023	0	48,358	Feb 14 09:46 PM
Gregory Ginger	EVP, Human Resources	Feb 10	Option Exercise	0.00	3,290	0	12,805	Feb 14 09:44 PM
Izzar Rachid	Head of Global Product Strat.	Feb 10	Option Exercise	0.00	1,968	0	6,359	Feb 14 09:41 PM
Kramer Robin	Chief Accounting Officer	Feb 10	Option Exercise	0.00	1,061	0	3,932	Feb 14 09:37 PM
MCDONNELL MICHAEL R	EVP, Chief Financial Officer	Feb 10	Option Exercise	0.00	3,256	0	10,001	Feb 14 09:25 PM
Murphy Nicole	Head of Pharm Ops and Tech	Feb 10	Option Exercise	0.00	2,611	0	6,379	Feb 14 09:23 PM
Singhal Priya	Head of Development	Feb 10	Option Exercise	0.00	1,211	0	3,863	Feb 14 09:21 PM
Kramer Robin	Chief Accounting Officer	Dec 08	Option Exercise	0.00	350	0	2,368	Dec 12 06:04 PM
Izzar Rachid	Head of Alzheimer's Disease	Dec 02	Option Exercise	0.00	1,710	0	3,395	Dec 06 06:37 PM
Murphy Nicole	Head of Pharm Ops and Tech	Dec 02	Option Exercise	0.00	131	0	2,807	Dec 06 06:33 PM
Gregory Ginger	EVP, Human Resources	Nov 14	Sale	300.11	5,610	1,683,617	5,711	Dec 12 08:00 PM
ALEXANDER SUSAN H	EVP Chief Legal Off & Corp Sec	Oct 27	Sale	280.70	5,532	1,552,832	39,396	Oct 28 07:19 PM
MCDONNELL MICHAEL R	EVP, Chief Financial Officer	Sep 01	Option Exercise	0.00	4,746	0	7,801	Sep 06 07:31 PM
BIOGEN INC.	10% Owner	Aug 30	Sale	5.27	100,000	526,520	23,652,466	Aug 31 07:03 PM
BIOGEN INC.	10% Owner	Aug 29	Sale	5.33	400,000	2,130,720	23,752,466	Aug 31 07:03 PM
Murphy Nicole	Head of Pharm Ops and Tech	Aug 01	Option Exercise	0.00	1,080	0	2,919	Aug 03 05:40 PM
Kramer Robin	Chief Accounting Officer	Jul 01	Option Exercise	0.00	252	0	2,092	Jul 06 07:33 PM
Izzar Rachid	Head of Alzheimer's Disease	Jul 01	Option Exercise	0.00	504	0	2,258	Jul 06 07:28 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience